Eli Lilly Meets Primary Endpoint in Late-Stage Pediatric Omvoh Trial

Metis TechBio, a Hong Kong-listed biotech, has partnered with Eli Lilly for up to $1.1 billion to develop AI-driven drug-delivery technologies. Metis will receive an upfront payment and potential milestone payments, plus royalties on sales. The collaboration aims to improve tissue targeting for LNP-based therapies.

Eli Lilly (LLY) plans to expand Omvoh's use for pediatric ulcerative colitis after a successful late-stage trial. The company aims to seek an indication extension for the therapy, which is currently approved for bowel disease. This follows a one-year study showing positive results in children with the inflammatory colon condition.

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

Eli Lilly (LLY) reported positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis, showing 81% clinical response and 50% remission rates. The company's GF Value™ suggests a 20.4% undervaluation, with a GF Score™ of 96/100. Insider selling totaled $2.66 billion over 12 months, while 25 gurus hold the stock with balanced activity. LLY's P/E ratio is 42.71x, below its 5-year median of 53.19x.

Eli Lilly (LLY) reported positive Phase 3 trial results for Omvoh in pediatric ulcerative colitis, meeting its primary endpoint. 50% of patients achieved clinical remission at one year. The company plans to submit results to regulators for potential label expansion. LLY stock closed at $1257.03 on October 16, 2026, and was down 1.05% in pre-market trading.

Eli Lilly (NYSE:LLY) reported that its drug Omvoh met the primary endpoint in a Phase 3 study for pediatric ulcerative colitis. The SHINE-2 study showed 81% of patients achieved clinical response at Week 12, with 50% of responders in clinical remission at Week 52. The company plans to submit the data to global regulators for potential label expansion. Omvoh is already approved for adults in 47 countries.